June 4 (NBD) -- Shenzhen Salubris Pharmaceuticals Co Ltd (002294.SZ) plans to take 473 million yuan (73.7 million U.S. dollars) out of its own pocket to buy a 100 percent stake in a Suzhou-based medical technology company, which principally engages in the research and development, manufacturing, and sale of medical devices for cardiac interventions, the listed company noted in a filing last Friday.  

Salubris expects to enrich its product range in the cardiovascular field through the new acquisition, which will be conducted in stages.

Email: lansuying@nbd.com.cn